Hilo's Bold Leap: Revolutionizing Blood Pressure Monitoring with $42 Million in New Funding
May 2, 2025, 3:38 pm
In the world of health technology, change is the only constant. Hilo, formerly known as Aktiia, has taken a giant leap forward, securing $42 million in a Series B funding round. This investment is not just a financial boost; it’s a lifeline for millions grappling with hypertension. The company aims to redefine blood pressure monitoring, making it as easy as checking your smartphone.
Hilo is not just a name change; it’s a mission. The rebranding reflects a broader ambition to make cuffless, clinically validated blood pressure monitoring accessible to everyone. With over 120,000 devices sold, Hilo has already carved a niche in the health tech landscape. The company’s innovative approach centers on a foundation machine learning model, meticulously trained on tens of billions of optical signals from real-world users. This model is further refined with hundreds of millions of calibration points, ensuring precision and reliability.
The urgency of Hilo’s mission cannot be overstated. Hypertension affects billions globally, yet only 20% of those afflicted manage to control it effectively. This stark reality underscores the need for innovative, user-friendly monitoring solutions. Hilo’s technology aims to bridge this gap, offering a convenient way for users to keep track of their blood pressure without the hassle of traditional cuffs.
The recent funding round was co-led by Earlybird Health and Wellington Partners, with participation from new investors Kfund and NaturalX Health Ventures, alongside existing backers like Khosla Ventures and Verve Ventures. This influx of capital brings Hilo’s total financing to over $100 million, a testament to investor confidence in its vision and technology.
Hilo’s growth trajectory has been impressive. The company has achieved a staggering 76% compounded annual revenue growth. It has also secured CE marking for its mobile phone camera-based blood pressure monitoring technology, paving the way for regulatory approvals in key markets like Canada, Australia, and Saudi Arabia. A pivotal clinical trial has been completed, setting the stage for an application to the U.S. FDA.
The new funding will accelerate product innovation and support the development of Hilo’s enterprise-focused blood pressure intelligence platform. This platform is designed to cater to businesses and healthcare providers, expanding Hilo’s reach and impact. The company is particularly focused on entering the German market, where it plans to launch new marketing channels to educate consumers about the health benefits of its technology.
Hilo’s commitment to innovation is evident in its approach to product development. The company is not just creating devices; it’s building a comprehensive ecosystem for blood pressure management. By leveraging machine learning and real-world data, Hilo aims to deliver accurate, actionable insights to users. This empowers individuals to take control of their health in a way that was previously unimaginable.
The rebranding to Hilo is more than a cosmetic change. It symbolizes a shift towards a more user-centered approach. The name itself evokes a sense of connection and support, aligning with the company’s mission to foster healthier blood pressure for all. Hilo’s technology is designed to be intuitive and easy to use, breaking down barriers that have traditionally hindered effective blood pressure monitoring.
As Hilo embarks on this new chapter, the company is keenly aware of the challenges ahead. The health tech landscape is competitive, with numerous players vying for attention. However, Hilo’s unique value proposition—cuffless, clinically validated monitoring—sets it apart. The company’s focus on user experience and data-driven insights positions it well for success in a crowded market.
The implications of Hilo’s technology extend beyond individual users. By providing healthcare providers with robust data and insights, Hilo can help improve patient outcomes on a larger scale. This aligns with a growing trend in healthcare towards data-driven decision-making, where real-time information can lead to more effective interventions.
In conclusion, Hilo’s recent funding and rebranding mark a significant milestone in the evolution of blood pressure monitoring. The company is poised to make a lasting impact on global health, offering innovative solutions to a pressing problem. With billions affected by hypertension, the need for accessible, accurate monitoring solutions has never been greater. Hilo is not just responding to this need; it is leading the charge, armed with cutting-edge technology and a commitment to empowering users worldwide. The journey ahead is filled with promise, and Hilo is ready to navigate the path to healthier blood pressure for all.
Hilo is not just a name change; it’s a mission. The rebranding reflects a broader ambition to make cuffless, clinically validated blood pressure monitoring accessible to everyone. With over 120,000 devices sold, Hilo has already carved a niche in the health tech landscape. The company’s innovative approach centers on a foundation machine learning model, meticulously trained on tens of billions of optical signals from real-world users. This model is further refined with hundreds of millions of calibration points, ensuring precision and reliability.
The urgency of Hilo’s mission cannot be overstated. Hypertension affects billions globally, yet only 20% of those afflicted manage to control it effectively. This stark reality underscores the need for innovative, user-friendly monitoring solutions. Hilo’s technology aims to bridge this gap, offering a convenient way for users to keep track of their blood pressure without the hassle of traditional cuffs.
The recent funding round was co-led by Earlybird Health and Wellington Partners, with participation from new investors Kfund and NaturalX Health Ventures, alongside existing backers like Khosla Ventures and Verve Ventures. This influx of capital brings Hilo’s total financing to over $100 million, a testament to investor confidence in its vision and technology.
Hilo’s growth trajectory has been impressive. The company has achieved a staggering 76% compounded annual revenue growth. It has also secured CE marking for its mobile phone camera-based blood pressure monitoring technology, paving the way for regulatory approvals in key markets like Canada, Australia, and Saudi Arabia. A pivotal clinical trial has been completed, setting the stage for an application to the U.S. FDA.
The new funding will accelerate product innovation and support the development of Hilo’s enterprise-focused blood pressure intelligence platform. This platform is designed to cater to businesses and healthcare providers, expanding Hilo’s reach and impact. The company is particularly focused on entering the German market, where it plans to launch new marketing channels to educate consumers about the health benefits of its technology.
Hilo’s commitment to innovation is evident in its approach to product development. The company is not just creating devices; it’s building a comprehensive ecosystem for blood pressure management. By leveraging machine learning and real-world data, Hilo aims to deliver accurate, actionable insights to users. This empowers individuals to take control of their health in a way that was previously unimaginable.
The rebranding to Hilo is more than a cosmetic change. It symbolizes a shift towards a more user-centered approach. The name itself evokes a sense of connection and support, aligning with the company’s mission to foster healthier blood pressure for all. Hilo’s technology is designed to be intuitive and easy to use, breaking down barriers that have traditionally hindered effective blood pressure monitoring.
As Hilo embarks on this new chapter, the company is keenly aware of the challenges ahead. The health tech landscape is competitive, with numerous players vying for attention. However, Hilo’s unique value proposition—cuffless, clinically validated monitoring—sets it apart. The company’s focus on user experience and data-driven insights positions it well for success in a crowded market.
The implications of Hilo’s technology extend beyond individual users. By providing healthcare providers with robust data and insights, Hilo can help improve patient outcomes on a larger scale. This aligns with a growing trend in healthcare towards data-driven decision-making, where real-time information can lead to more effective interventions.
In conclusion, Hilo’s recent funding and rebranding mark a significant milestone in the evolution of blood pressure monitoring. The company is poised to make a lasting impact on global health, offering innovative solutions to a pressing problem. With billions affected by hypertension, the need for accessible, accurate monitoring solutions has never been greater. Hilo is not just responding to this need; it is leading the charge, armed with cutting-edge technology and a commitment to empowering users worldwide. The journey ahead is filled with promise, and Hilo is ready to navigate the path to healthier blood pressure for all.